Fig 6. Effects of oxaliplatin treatment on the fluorescence and number of CD45⁺ immune cells, and MPO activity in the colon.

Colon cross-sections (30μm thick) from the vehicle and oxaliplatin-treated groups were labelled with the pan-leukocyte marker anti-CD45 antibody (green) (A-B: scale bars = 50μm). The numbers of CD45+ cells were counted from 8 images per preparation taken at 20x magnification with a total area of 2mm². No significant differences in the total number of CD45⁺ cells (C), or immunoreactivity (D) within the colon is observed between the vehicle-treated and oxaliplatin-treated cohorts, n = 4-5/group. To determine whether oxaliplatin treatment caused inflammation within the colon specific to neutrophils or macrophages a MPO assay was conducted. Oxaliplatin treatment did not induce any significant changes to MPO activity within the colon when compared to the vehicle-treated cohort (E). N = 4/group.